RenovoRx Inc. is a biopharmaceutical company focused on the development of innovative cancer therapies. Its primary mission is to improve the survival outcomes and quality of life for patients diagnosed with difficult-to-treat cancers. The company is particularly known for its proprietary Trans-Arterial Micro-Perfusion (TAMP) platform, which is designed to deliver targeted chemotherapy directly to tumors, enhancing treatment efficacy while minimizing systemic exposure and associated toxicities. RenovoRx is pioneering breakthroughs in targeted intra-arterial chemotherapy, especially for pancreatic cancer, which is known for its low survival rates and limited treatment options. With its novel approach, RenovoRx aims to transform the therapeutic landscape within oncology. Positioned within the biotechnology sector, the company plays a significant role in advancing precision medicine, offering hope for improved patient outcomes through tailored therapeutic strategies. As a cutting-edge player in the sector, RenovoRx continues to explore regulatory pathways and conducts clinical trials to validate its approaches and seek approvals for broader clinical use.